Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — Study Reveals No Major Change in Youth Cannabis Use Following Legalization in Canada

A recent study, featured in the JAMA Open Network, has shed light on the impact of marijuana legalization in Canada, specifically concerning its effects on young individuals and potential adverse consequences. The research, conducted in Ontario, focused on a cohort of young adults aged between 19.5 to 23 years, aiming to understand changes in marijuana consumption patterns and related outcomes. Over the span of three years, from February 2017 to February 2020, the researchers conducted surveys every four months, collecting data that encompassed both the pre- and post-legalization periods.

The study involved 619 participants, with an average age of 21 and a standard deviation of 1.2 years. Approximately 56% were female, and 53% held bachelor’s degrees at the latest recorded time point. Notably, before legalization, around 33% reported occasional marijuana use as the norm.

Contrary to concerns about a surge in marijuana use among young people following legalization, the study revealed an overall reduction in marijuana use. This decline in consumption aligns with the existing substance-use patterns within this age group, unaffected by the policy change brought about by legalization.

Interestingly, the most frequent marijuana users before legalization experienced a significant decrease in usage following the legal transition. Consequently, there was a marked decrease in cannabis-related adverse consequences reported among the group. This suggests that the legalization of marijuana may have led to more responsible use among those who were previously heavy users.

On the other hand, individuals who abstained from cannabis use in the period leading up to legalization exhibited a modest but noteworthy increase in consumption over time. Importantly, this increase in use did not result in a corresponding surge in adverse consequences, challenging the notion of increased risks associated with cannabis legalization.

Those who had refrained entirely from using cannabis before legalization experienced no significant increases in negative consequences or usage post-legalization. These observations highlight the complexity of factors influencing marijuana use among young adults and suggest that further research is necessary to fully understand the determinants at play.

This study represents the first longitudinal analysis of the impact of marijuana legalization on young adults in Canada, incorporating multiple time points both before and after legalization.

It is, however, consistent with several U.S. studies that show state marijuana legalization has not significantly changed the consumption habits of adolescents and young people. Over the past 10 years, federal and state data have consistently shown a drop in the overall rate of youth marijuana usage.

This study goes to show that those who regard cannabis companies such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) as possibly doing harm to youth have no justification for their attitude to marijuana legalization.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Ongoing Diabetes Study Program to Examine its Patented DehydraTECH(TM) Technology with Launch of Human and Animal Studies for Oral GLP-1 Drugs

Lexaria recently announced its intention to launch new human and animal studies exploring its patented DehydraTECH(TM) technology on GLP-1 drugs for the potential treatment of diabetes
The studies will build on what Lexaria has achieved so far since it started its diabetes-related studies in 2022
Its DehydraTECH-CBD demonstrated an almost three-fold improvement in drug delivery into the blood in its DIAB-A22-1 diabetes study compared to the DehydraTECH-CBD formulation used in its HYPER-H21-4 hypertension study
These studies follow Lexaria’s announcement of its intention to study weight loss and diabetes control in a human population using DehydraTECH

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its intention to launch new human and animal studies that will explore its patented DehydraTECH(TM) technology on glucagon-like peptide-1 (“GLP-1”) drugs for improved bioavailability, cost-effectiveness, tolerability, weight loss potential, management of diabetes and other health conditions. Regarded as a significant expansion for Lexaria, these studies will build on what the company has achieved so far with its DehydraTECH-processed CBD while examining the technology’s impact on GLP-1 drugs (https://cnw.fm/Np3FA).

The U.S. Food and Drug Administration (“FDA”) recently approved GLP-1 drugs for type 2 diabetes and weight loss management following their demonstration of an average loss of 15% of body weight across 667 individuals in a 68-week-long study. The drug has also demonstrated that some patients experience reduced cravings for alcohol, nicotine, and opioids while taking the drugs, with other trials showing the reduced build-up of proteins amyloid and tau in the brain, both thought to be partly responsible for Alzheimer’s.

Despite their overall potential, GLP-1 drugs have many side effects, ranging from mild ones, such as nausea and vomiting, to more serious ones, such as reduced bone density and muscle loss. Some of the more severe side effects have been reported when the drugs are taken in oral form, which has prompted researchers and medical practitioners to treat patients with lower oral doses. Given the overall nature of GLP-1 drugs to have low oral bioavailability, Lexaria, through its DehydraTECH technology, looks to address that, ultimately improving the drug’s pharmacokinetic (“PK”) performance.

In the recently completed DIAB-A22-1 diabetes study, Lexaria demonstrated an almost three-fold improvement in drug delivery into the blood compared to the DehydraTECH-CBD formulation used in its HYPER-H21-4 hypertension study. With such results in this and five other human clinical studies, Lexaria has proven severally that its technology can significantly improve the PK performance of many orally administered drugs into the bloodstream. Its applications have ranged from cannabinoids, estradiol, PDE-5 Inhibitors, and certain antiviral drugs. The company is optimistic about the technology’s application, GLP-1, and its potential to improve its bioavailability.

The animal and human clinical studies on GLP-1 will be a logical progression to Lexaria’s efforts to explore DehydraTECH in the potential treatment of diabetes, which kicked off in 2022. In its pre-clinical study DIAB-A22-1, DehydraTECH-CBD has yielded a 19.9% lowered blood glucose level, a 7% lowered overall body weight sustained over eight weeks, increased locomotor activity, lowered triglyceride levels by more than 25%, and lowered blood urea nitrogen levels by 27.9%. Given its intention to study weight loss and diabetes control in a human population using DehydraTECH, as announced on August 2, 2023, the GLP-1 studies come at the opportune time, facilitating this specific objective.

Program design for the GLP-1 study has already commenced, and initial study work is set to begin as soon as possible. This ambitious step affirms Lexaria’s commitment to creating shareholder value and advancing its technology to become a leader in its segment.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Georgia State Residents Could Soon Access Medical Cannabis in Pharmacies

Officials in Georgia recently announced that the state would begin to provide medical cannabis products in pharmacies statewide. Last week, the state’s pharmacy board started accepting applications for independent pharmacies that wanted to take part in the exercise. Once applications have been submitted, all pharmacies will have to undergo inspection before they can receive approval from the board.

Thus far, almost 120 drugstores have agreed to provide drugs from Botanical Sciences, one of the licensed production companies in the state. It is expected that it will take a couple of weeks before medical cannabis is available in pharmacies. At the moment, medical cannabis is available to individuals in the state who have received approval from a physician for the treatment of serious illnesses such as post-traumatic stress disorder, Parkinson’s disease, seizures and terminal cancers.

THC oil should contain no more than 5% THC, which is one of the two major compounds found in marijuana. The expansion of medical marijuana sales into pharmacies will allow many more patients to access THC oil, which adds to the seven dispensaries in the state that have launched since April. Individuals will be able to purchase THC oil at drug stores once they present a state-issued registry card and identification.

Botanical Sciences notes that nearly 90% of the population in the state live within a half-hour drive of a pharmacy that sells medical cannabis. Mindy Leech, a pharmacist in Newnan, stated that this move by the state would help destigmatize medical marijuana while also making it more comfortable for customers to ask questions about the drugs.

In 2019, the Georgia General Assembly approved the distribution of low THC oil. However, it’s taken years to establish regulations for inspections, safety, licensing and distribution.

In other news, the state’s department of public health recently revealed that it had misreported the number of registered medical cannabis patients in Georgia. The inflated figure, 50,000, is far higher than the 14,000 individuals who have signed up for the program.

Jonathan Marquess, Georgia Pharmacy Association VP, stated that patients who didn’t have dispensaries near them would be able to access this healthcare. Marquess, who owns a number of pharmacies in the Atlanta area, noted that with more than 400 independent pharmacies in the state, most would be interested in selling cannabis oil given that the product isn’t being sold in drugstores such as Walgreens and CVS.

Georgia Access to Medical Cannabis Commission’s executive director Andrew Turnage added the pharmacy rule would help licensees as well as patients.

A time will come when states such as Georgia will fully reform their marijuana laws so that local companies can also enjoy the kind of success that enterprises such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) have earned for themselves in the markets in which they operate.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — DOJ Defends Ban on Gun Rights of Medical Cannabis Users in Federal Appeals Court

A federal court of appeals recently held oral arguments in a case addressing the constitutionality of the federal ban that prevents medical cannabis patients from buying or owning firearms. The proceedings unfolded before a three-judge panel of the U.S. 11th Circuit Court of Appeals, where lawyers representing the Justice Department and Florida’s medical marijuana patients presented their respective arguments. The case has been extensively discussed through numerous briefings spanning over a year.

The plaintiffs’ attorney, Will Hall, outlined two key reasons supporting the federal ban’s unconstitutionality. Firstly, Hall argued that regardless of whether marijuana usage is lawful, committing a crime does not automatically deprive people of their Second Amendment rights. Secondly, he asserted that the Supreme Court has established new standards for evaluating gun limitations, declaring them illegal unless they are consistent with the historical background of the Second Amendment, which was passed in 1791. Hall said that prohibiting people who use medical cannabis is inconsistent with this historical setting.

While the Justice Department’s counsel conceded that illegal drugs were not widely used when the law was set, he argued that early laws restricting gun rights because of conditions such as mental health and intoxication serve as historical precedents consistent with the goal of the federal gun ban for regular cannabis users.

The discussion also delved into the definition of a law-abiding person whose Second Amendment rights should be safeguarded. One of the judges observed that it would seem incongruous to categorize state-registered medicinal cannabis patients as not adhering to the law in light of the federal rider, which has been extended yearly since 2014 and bans DOJ involvement in state medical-marijuana programs.

Both parties and judges acknowledged that the forthcoming Supreme Court case, U.S. vs. Rahima, which addresses the disarming of individuals with domestic violence injunctions, could influence the ruling in this case by clarifying whether Second Amendment rights can be systematically denied to nonlaw-abiding individuals for whatever reason.

The hearing also referenced a ruling by the U.S. Fifth Circuit Court of Appeals in Daniels vs. the U.S., which declared the ban on marijuana users possessing firearms unconstitutional, even for recreational cannabis users. The DOJ expressed disagreement with this ruling, reiterating its reservations about the foundation of the decision.

The plaintiffs in the current case are seeking a narrow declaration, distinct from Daniels, specifically addressing state medical marijuana patients who are law compliant.

Several district court rulings have also questioned the constitutionality of the firearms ban for marijuana users, including cases in Oklahoma and Texas. Additionally, the ATF has voiced concerns regarding state laws allowing medical marijuana patients to obtain concealed carry gun licenses, citing potential risks and conflicts with federal firearm licensing policies.

Major marijuana companies such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) are likely to follow this court case keenly since it would address one of the big concerns that many people have about using state-legal marijuana products, which are regarded illegal by the federal government.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Inks Global Collaboration, License Agreement with SulfoSyn

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has granted a new global, exclusive license to SulfoSyn Limited; the license is for the exclusive global use of all nonpharmaceutical applications of Lexaria’s proprietary DehydraTECH-sulforaphane, including the right to authorize sublicenses. According to the announcement, Lexaria has already received an up-front cash payment, and the agreement outlines minimumongoing payments, royalties and manufacturing revenues. Nonpharmaceutical uses could include supplements, additives, foods, dietary ingredients and more. In addition to the license agreement, the two companies have a broader agreement that, for at least the next two years, Lexaria will conduct certain DehydraTECH-related manufacturing operations at its U.S. partner facility on behalf of SulfoSyn, which should also result in an increase in revenue to Lexaria. The announcement noted that the two companies started exploring the applicability of DehydraTECH upon sulforaphane late last year; results of that indicate that DehydraTECH confers certain superior qualities upon the sulforaphane molecule that are of commercial interest.

To view the full press release, visit https://cnw.fm/IiAI3

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Advocates, Lawmakers Push Biden for More Action as His Mass Pardons Order Reaches Year Mark

One year after President Joe Biden ordered a mass cannabis pardon and called for a review of marijuana’s status at the federal level, advocates and lawmakers are pushing for more marijuana action. President Biden based part of his campaign on cannabis reform and pledged to do things such as pardon Americans with cannabis-related convictions, something his administration set out to do a year ago.

However, cannabis advocates and lawmakers have long argued that the administration could do more to further cannabis reform in the country, calling on the Biden administration to fulfill its cannabis promises in full and on time.

Most agree that last year’s mass pardon followed by the directive to review marijuana’s federal status were major steps in the right direction. However, now that the mass pardon’s first anniversary has arrived, activists and lawmakers are urging the administration to take its cannabis action even further with the ultimate goal of finally putting an end to federal cannabis prohibition.

According to Congressional Cannabis Caucus cochair Representative Earl Blumenauer, the president must “send a clearer signal” that he fully supports cannabis legalization at the federal level. While Biden’s pardon and his call for a scheduling review were a critical step in the right direction, Blumenauer said “more is needed” to further cannabis reform in the country. This includes prioritizing efforts by Congressional lawmakers to “rationalize” America’s federal marijuana laws and reissuing Cole Memo protections, Blumenauer said.

Although last year’s mass cannabis pardons would theoretically benefit several thousand Americans saddled with cannabis possession on their records, advocates quickly pointed out that communities such as immigrants would be left out of the pardons. The 2022 pardons did not apply to people in federal prison, meaning people who are currently incarcerated in federal prisons for cannabis possessions have not been released. Furthermore, the pardon will not prevent Americans from being persecuted for cannabis possession in the future.

Cannabis Caucus cochair Representative Dave Joyce noted that while the federal government has indicated that it is keen on updating its approach to cannabis, he has seen little application of the administration’s rescheduling and expungement efforts over the past year. Consequently, Joyce said, he is “laser focused” on advancing bipartisan marijuana legislation in Congress to grant the state-level cannabis industry access to banking, incentivize cannabis expungement at the state level and prepare the federal government for marijuana legalization.

According to Joyce, such cannabis measures will force the Biden administration to take action and provide relief to the Americans still suffering from “unjust federal prohibition.”

Companies such as Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) founded in Canada where marijuana is legal nationally hope that their neighbor, the United States, can also reform its cannabis laws so that citizens can benefit from this industry on a bigger scale through employment, entrepreneurship and so on.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Mismatch Grows Between the Public’s Interest In, Education About Cannabis

Public perceptions about cannabis have come a long way over the past couple of decades. For the generations that grew up during the war on drugs era, cannabis was framed as a dangerous illicit drug that acted as a gateway to more hardcore drug use and increased criminal activity in communities. However, as states such as California began legalizing cannabis for medical use over two decades ago and state-level cannabis criminalization steadily reduced, attitudes toward cannabis across the country began to improve.

These days, most nationwide polls show that the majority of the country is in favor of legalizing medical cannabis use or at least decriminalizing the use and possession of marijuana.

Despite the fact that marijuana enjoys growing nationwide support, there seems to be a mismatch between public interest and accurate cannabis knowledge. In fact, with support for cannabis growing, the gap between public interest in the controversial drug and education about it seems to be growing even faster.

This gap is largely caused by the proliferation of misinformation and inaccurate information in America’s state-level cannabis industry, resulting in a population that has an immense interest in cannabis but doesn’t always receive the right information regarding the plant. On the other end of the spectrum are members of the public who are interested in cannabis but have no strong inclination to learn.

Some misconceptions about cannabis have become so entrenched that budtenders, or individuals tasked with knowing the most about cannabis and informing interested customers, often talk about things such as the “indica and sativa effect,” even though they aren’t scientifically accurate.

Another aspect of the nascent cannabis sector that is rife with misinformation is THC potency in cannabis and cannabis-infused products. With extraction methods becoming more refined in recent years, cannabis companies are developing increasingly potent THC products.

Many companies tout their products’ high THC levels as a top selling point to capitalize on the public’s increasing obsession with high THC products. A lot of these companies claim to be interested in teaching consumers about cannabis, but they continue to push high-THC cannabis strains as high-quality products without stating their potential side effects.

Conflating high-THC products with the industry standard has led many consumers to mistakenly believe that more potent cannabis products are inherently superior to low-THC products. This assumption causes many to miss out on the purported benefits of consuming whole cannabis with all the cannabinoids (including THC), terpenes, flavonoids and other plant compounds.

Local, state and federal entities now need to work with industry actors such as Tilray Brands Inc. (NASDAQ: TLRY) to bridge the information gap evident within the members of the public.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Portfolio Expansion to 37 Granted Patents

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has been granted two new patents by the Canadian Intellectual Property Office (“CIPO”), increasing its portfolio to 37 granted patents. According to the update, Canadian Patent #2,984,917, “ Stable Ready-to-drink Beverage Compositions Comprising Lipophilic Active Agents, ” was granted on Sept. 26, 2023, and expires Dec. 1, 2036. The patent recognizes Lexaria’s innovations in delivering lipophilic (fat-based) active drugs and active molecules suspended in a water-based format. Lexaria’s DehydraTECH technology can be used in dry formats such as capsules and pills, as well as in liquid formats such as drops, tinctures and also beverages including consumer beverages. This is the company’s sixth granted patent in its patent family.

To view the full press release, visit https://cnw.fm/2qhs4

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Marijuana Testing Scrutinized as Product Recalls, Differing Rules Draw Attention

State cannabis authorities, producers and various stakeholders are currently contending with the challenge of ensuring consumer safety in an environment where lab-testing regulations and enforcement practices vary widely across the nation, resulting in frequent large-scale product recalls.

At present, each state adopts its own approach to conducting lab tests for both medical and recreational cannabis, assessing inspections, potency, contaminants and production standards. This fragmented approach has led to inconsistent regulations for testing and raised concerns about whether safeguarding consumers truly ranks as a top priority for industry players.

Americans for Safe Access (ASA) founder Steph Sherer attributes this patchwork approach to the overarching federal prohibition of cannabis.

Medical marijuana producers in Maine have contended that their products are inherently safe and, therefore, should be exempt from mandatory testing, despite two separate analyses revealing high levels of pesticides and contaminants in their samples, rendering them unfit for sale in the regulated adult-use market.

Arizona has also faced multiple recalls this year due to potential salmonella and aspergillus contamination in marijuana flowers and processed products. Experts suggest that such recalls could be prevented through the implementation of more stringent marijuana lab standards, the establishment of a statewide tracking system or adherence to Good Manufacturing Practice (GMP) standards.

In Oregon, the Liquor and Marijuana Commission decided to permit the sale of products testing positive for aspergillus, a type of mold responsible for product recalls in several markets. This decision came after a lawsuit filed by cultivators arguing that enforcing the state’s new zero-tolerance policy for aspergillus would drive them out of business.

Sherer criticized the commission’s decision, describing it as “criminal.” Aspergillus may not harm healthy individuals, he said, but those with compromised immune systems or lung diseases face a higher risk of infection.

To address this situation, some experts propose the use of irradiation to eliminate contaminants such as mold. However, concerns persist that such processes may compromise product quality, underscoring the need to balance consumer safety with personal responsibility.

The potential rescheduling of marijuana from a Schedule 1 to a Schedule 3 drug by the DEA could be a key step toward federal oversight of marijuana testing and production standards. ASA envisions the creation of a federal office of medical marijuana under the U.S Department of Health and Human Services (HHS), which would collaborate with state governments to formulate comprehensive cannabis testing requirements.

The regulation of cannabinoid-containing products, on the other hand, remains complex, as demonstrated by the slow progress in overseeing CBD products since the passage of the 2018 Farm Bill. It remains unclear how lab standards would evolve following rescheduling.

Marijuana enterprises such as Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) would appreciate uniform nationwide standards that bring uniformity to cannabis products sold in any of the markets where such products are legal because such regulations would clear a lot of uncertainty in the rules players have to conform to.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Finds Entourage Effect of Marijuana Triggers More Intense High Than THC Alone

When many people contemplate the euphoria induced by marijuana consumption, their thoughts inevitably gravitate toward THC, the plant’s principal psychoactive constituent. However, a recent study lends support to the notion of the “entourage effect,” demonstrating that marijuana products containing a wider variety of natural cannabinoids result in an even more potent psychoactive high than those made from pure THC.

This research used innovative electroencephalogram (EEG) technology, augmented by AI capabilities, to gauge the euphoria that individuals experienced while vaporizing two distinct products. The first was a full-spectrum live rosin with an average concentration of 85% THC, complemented by other natural terpenes and cannabinoids. The second was a high-purity THC oil boasting a potency range of 82% to 85%.

Twenty-eight adults took part in the study, donning EEG headsets created by the marijuana technology company Zentrela. The participants ingested two hits (8 mg) of the first or second product through a vape made by PAX, which also sponsored the research.

Before consuming the products, the participants underwent a baseline reading. Over the ensuing 90 minutes, the EEG observed cerebral activity across eight distinct brain regions. Subsequently, the collected data were translated into psychoactive effect levels (PEL), which are expressed on a standard scale ranging from 0% to 100%. The outcomes unveiled that the full-spectrum live rosin, containing THC along with other terpenes and cannabinoids, exhibited a slightly swifter onset: three minutes. Results showed a potency reading of 20.8% at the outset and even more substantial potencies at the 15-minute peak (40%) and 90-minute mark (30.2%).

On the other hand, the pure THC product exhibited an average onset time of four minutes with an initial potency of 13.5%. At its peak, the potency registered at 19.1%, subsequently declining to 18.1%.

In essence, the study, while yet to undergo peer review or publication in a scientific journal, lends credence to the entourage effect hypothesis. It suggests that cannabis containing a more varied composition of its innate constituents yields a more potent experience. This finding holds significance for patients, as the entourage effect could potentially fortify specific therapeutic applications.

Brian Witlin, PAX’s vice president of product development, stated in a press release, “Consumers seeking psychoactive effects frequently base their choices on THC content, which is somewhat misleading.”

Beyond enhancing consumer awareness, the study’s findings can also empower marijuana companies to devise more targeted products by harnessing data regarding the distinct combinations of cannabinoids that engender diverse effects.

This study isn’t the first to spotlight the comparative advantages of diverse marijuana products. In 2018, a study revealed that patients with epilepsy who utilize plant-based CBD extracts as opposed to refined CBD products have better health results and experience fewer negative side effects.

For companies that sell whole-flower products, such as SNDL Inc. (NASDAQ: SNDL), the study’s findings that the entourage effect triggers more intense experiences for cannabis users makes a case for the continued development of products that leverage the entire spectrum of cannabinoids and other constituents rather than individual compounds.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com